Literature DB >> 1184745

Effect of corticosteroids on the human monocyte IgG and complement receptors.

A D Schreiber, J Parsons, P McDermott, R A Cooper.   

Abstract

A quantitative in vitro assay was employed to directly assess the effect of corticosteroids on the IgG and complement receptor function of human mononuclear phagocytic cells. In this system corticosteroids were solubilized with cholesterol-phospholipid sonicated dispersions before exposure to mononuclear cells. Solubilized corticosteroids at concentrations between 10(-4) and 10(-3) M inhibited both IgG and complement receptor activity in a dose-response fashion. Inhibition was dependent upon the time of interaction of the mononuclear cells with corticosteroids and was half-maximal by 15 min. The inhibitory effect at all concentrations of hydrocortisone was partially overcome by increasing the number of IgG molecules per erythrocyte. Hydrocortisone also inhibited the binding of erythrocytes coated with both IgG and C3, despite the fact that when both were on the erythrocyte surface a synergistic effect on binding to mononuclear cells was observed. At the steroid concentrations employed, the capacity of mononuclear cells to exclude trypan blue and to take up latex particles and neutral red was unaffected. Mineralocorticoids also inhibited receptor activity, but the sex hormones were less effective. These studies demonstrate an effect of steroid hormones on cell membrane receptor function, and they suggest that an inhibition of the recognition system for IgG and C3 in vivo may explain, in part, the effect of corticosteroids in man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184745      PMCID: PMC301983          DOI: 10.1172/JCI108196

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Modification of red cell membrane structure by cholesterol-rich lipid dispersions. A model for the primary spur cell defect.

Authors:  R A Cooper; E C Arner; J S Wiley; S J Shattil
Journal:  J Clin Invest       Date:  1975-01       Impact factor: 14.808

Review 2.  Phagocytosis (third of three parts).

Authors:  T P Stossel
Journal:  N Engl J Med       Date:  1974-04-11       Impact factor: 91.245

3.  Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone.

Authors:  J P Atkinson; M M Frank
Journal:  Blood       Date:  1974-11       Impact factor: 22.113

4.  Cellular immunity after intravenous administration of methylprednisolone.

Authors:  M L Webel; R E Ritts; H F Taswell; J V Danadio; J E Woods
Journal:  J Lab Clin Med       Date:  1974-03

5.  Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G.

Authors:  H Huber; M J Polley; W D Linscott; H H Fudenberg; H J Müller-Eberhard
Journal:  Science       Date:  1968-12-13       Impact factor: 47.728

6.  Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites.

Authors:  A D Schreiber; M M Frank
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

7.  Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man.

Authors:  J P Atkinson; M M Frank
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

8.  Effects of corticosteroids on human monocyte function.

Authors:  J J Rinehart; S P Balcerzak; A L Sagone; A F LoBuglio
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Receptor for the fourth component of complement on human B lymphocytes and cultured human lymphoblastoid cells.

Authors:  V A Bokisch; A T Sobel
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

View more
  44 in total

1.  Effect of methylprednisolone on coagulation.

Authors:  H B Pandit; C R Spillert
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

Review 2.  Immunological aspects of antiviral therapy.

Authors:  M Peters
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3.

Authors:  Zhen-Yu Huang; Sharon Hunter; Paul Chien; Moo-Kyung Kim; Tae-Hee Han-Kim; Zena K Indik; Alan D Schreiber
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

4.  Pathogenesis of hemolysis in immune hemolytic anemia.

Authors:  J R Cohen
Journal:  West J Med       Date:  1977-10

5.  Effects of surface-active agents on neutrophil receptors.

Authors:  L A Boxer; S B Richardson; R L Baehner
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

6.  Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor.

Authors:  P Chien; R A Pixley; L G Stumpo; R W Colman; A D Schreiber
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  Human monocyte-lymphocyte interaction and its enhancement by levamisole.

Authors:  J W Kazura; W Negendank; D Guerry; A D Schreiber
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

Review 8.  Phagocytosis. Clinical disorders of recognition and ingestion.

Authors:  T P Stossel
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

9.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

Authors:  K M Skubitz; P R Craddock; D E Hammerschmidt; J T August
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

Review 10.  Steroids, aspirin, and inflammation.

Authors:  E Katler; G Weissmann
Journal:  Inflammation       Date:  1977-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.